Glycemia in Diabetic Elders Trial


This study is a pilot randomized controlled trial of 30 elderly type 2 diabetes patients conducted at the MODEL Clinical Research (MODEL), Research Division of Bay West Endocrinology Associates in Baltimore, Maryland. The investigators hypothesized that compared to a regimen base solely on traditional drugs, a regimen including newer drugs will achieve glycemic target faster and induce less hypoglycemia, weight gain, and other side effects, over the short run.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: February 2017


  • Drug: Standard Treatment
    • traditional drugs only
  • Drug: Incretin-Based Treatment
    • incretin-based drugs

Arms, Groups and Cohorts

  • Active Comparator: Standard Treatment
    • A regimen with traditional drugs only
  • Experimental: Incretin-based Treatment
    • A regimen including incretin-based drugs

Clinical Trial Outcome Measures

Primary Measures

  • Time to Achieve Glycemic Target (HbA1c <7.5%).
    • Time Frame: 6 months
    • Data not analyzed due to n=1 each arm.

Secondary Measures

  • Overall Hypoglycemia Measured by Glucose Meter
    • Time Frame: 6 months
    • Data not analyzed due to n=1 each arm.

Participating in This Clinical Trial

Inclusion Criteria

  • Type 2 diabetics diagnosed for at least 6 months
  • Patients ages ≥ 65 years and older
  • Active patients in the Bay West Endocrinology practice
  • Inadequately controlled on oral agents and/or basal insulin with HbA1c between 8.0% and 12%
  • Eligible for randomization to either treatment group
  • Patients willing to follow either treatment arm including regimen using one or more injectables
  • Patients to have an English Reading Level of Grade 6 or above
  • Patients residing at home

Exclusion Criteria

  • Unwilling to use a regimen that may contain using one or more injections
  • Using short acting insulin prior to the study
  • Using GLP-1 in past 10 weeks
  • History of hypoglycemia unawareness or episodes needing emergency intervention
  • End-stage renal disease
  • Dementia
  • Blindness
  • Terminal illness

Gender Eligibility: All

Minimum Age: 65 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Johns Hopkins University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Hsin-Chieh Yeh, PhD, Principal Investigator, Johns Hopkins University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.